Tempest Therapeutics, Inc.
TPST
$10.03
$0.6757.22%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.10M | 3.31M | 3.18M | 2.99M | 3.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.97M | 10.94M | 13.92M | 10.55M | 9.58M |
| Operating Income | -7.97M | -10.94M | -13.92M | -10.55M | -9.58M |
| Income Before Tax | -7.87M | -10.86M | -13.81M | -10.56M | -9.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.87M | -10.86M | -13.81M | -10.56M | -9.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.87M | -10.86M | -13.81M | -10.56M | -9.57M |
| EBIT | -7.97M | -10.94M | -13.92M | -10.55M | -9.58M |
| EBITDA | -7.90M | -10.87M | -13.87M | -10.45M | -9.43M |
| EPS Basic | -2.07 | -3.16 | -4.38 | -5.32 | -5.52 |
| Normalized Basic EPS | -1.29 | -1.97 | -2.74 | -3.32 | -3.45 |
| EPS Diluted | -2.07 | -3.16 | -4.38 | -5.32 | -5.52 |
| Normalized Diluted EPS | -1.29 | -1.97 | -2.74 | -3.32 | -3.45 |
| Average Basic Shares Outstanding | 3.80M | 3.44M | 3.15M | 1.99M | 1.73M |
| Average Diluted Shares Outstanding | 3.80M | 3.44M | 3.15M | 1.99M | 1.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |